Titre : Vinblastine

Vinblastine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Proctectomy

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?

La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués.
Vinblastine Cancer Diagnostic médical
#2

Quels tests précèdent l'administration de vinblastine ?

Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement.
Tests de laboratoire Imagerie médicale Vinblastine

Symptômes 2

#1

Quels sont les effets secondaires courants de la vinblastine ?

Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux.
Effets secondaires Vinblastine Nausées
#2

La vinblastine provoque-t-elle des douleurs ?

Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique.
Douleur Vinblastine Effets indésirables

Prévention 2

#1

La vinblastine a-t-elle un rôle préventif dans le cancer ?

Non, la vinblastine est un traitement et ne prévient pas le développement du cancer.
Prévention du cancer Vinblastine Traitement
#2

Peut-on prévenir les effets secondaires de la vinblastine ?

Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine.
Effets secondaires Vinblastine Médicaments antiémétiques

Traitements 2

#1

Dans quels types de cancer la vinblastine est-elle utilisée ?

Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule.
Lymphome Cancer du poumon Vinblastine
#2

Comment la vinblastine est-elle administrée ?

La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale.
Administration intraveineuse Vinblastine Traitement du cancer

Complications 2

#1

Quelles complications peuvent survenir avec la vinblastine ?

Des complications incluent des infections, des saignements et des problèmes neurologiques.
Complications Vinblastine Infections
#2

La vinblastine peut-elle affecter la moelle osseuse ?

Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs.
Moelle osseuse Vinblastine Dépression médullaire

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables avec la vinblastine ?

Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru.
Facteurs de risque Vinblastine Maladies cardiaques
#2

Les enfants peuvent-ils prendre de la vinblastine ?

Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance.
Vinblastine Pédiatrie Traitement du cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vinblastine : Questions médicales les plus fréquentes", "headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-10", "dateModified": "2025-05-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vinblastine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vinblastine", "alternateName": "Vinblastine", "code": { "@type": "MedicalCode", "code": "D014747", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Christine Chevreau", "url": "https://questionsmedicales.fr/author/Christine%20Chevreau", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Oncopole, Toulouse, France." } }, { "@type": "Person", "name": "Stéphane Culine", "url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr." } }, { "@type": "Person", "name": "Gwenaelle Gravis", "url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France." } }, { "@type": "Person", "name": "Florence Joly", "url": "https://questionsmedicales.fr/author/Florence%20Joly", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Neorectal prolapse following proctectomy: a novel application of mesh sacral pexy.", "datePublished": "2023-05-20", "url": "https://questionsmedicales.fr/article/37210428", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10151-023-02805-2" } }, { "@type": "ScholarlyArticle", "name": "Outcomes after transanal proctectomy with ileal pouch-anal anastomosis in adolescents.", "datePublished": "2023-01-25", "url": "https://questionsmedicales.fr/article/36695985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00383-023-05381-6" } }, { "@type": "ScholarlyArticle", "name": "Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36538720", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DCR.0000000000002555" } }, { "@type": "ScholarlyArticle", "name": "Seniority of the assistant surgeon and perioperative outcomes in robotic-assisted proctectomy for rectal cancer.", "datePublished": "2022-12-31", "url": "https://questionsmedicales.fr/article/36586036", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11701-022-01515-5" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for ischemia/necrosis of the colonic stump after proctectomy and delayed coloanal anastomosis.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/37910292", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00423-023-03157-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vinblastine", "item": "https://questionsmedicales.fr/mesh/D014747" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vinblastine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vinblastine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vinblastine", "description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Proctectomy#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vinblastine", "description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Proctectomy#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vinblastine", "description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Proctectomy#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vinblastine", "description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Proctectomy#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vinblastine", "description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Proctectomy#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vinblastine", "description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Proctectomy#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vinblastine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la vinblastine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux." } }, { "@type": "Question", "name": "La vinblastine provoque-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vinblastine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine." } }, { "@type": "Question", "name": "Dans quels types de cancer la vinblastine est-elle utilisée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule." } }, { "@type": "Question", "name": "Comment la vinblastine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vinblastine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des saignements et des problèmes neurologiques." } }, { "@type": "Question", "name": "La vinblastine peut-elle affecter la moelle osseuse ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables avec la vinblastine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru." } }, { "@type": "Question", "name": "Les enfants peuvent-ils prendre de la vinblastine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 05/05/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Eric Bouffet

2 publications dans cette catégorie

Affiliations :
  • Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.

Yaser Hassan Dewir

2 publications dans cette catégorie

Affiliations :
  • Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Sarah E O'Connor

2 publications dans cette catégorie

Affiliations :
  • Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.

G A Amos Burke

2 publications dans cette catégorie

Affiliations :
  • Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

Riccardo Finotello

2 publications dans cette catégorie

Affiliations :
  • Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.

Yoshihiro Nishida

2 publications dans cette catégorie

Affiliations :
  • Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Shunsuke Hamada

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Tomohisa Sakai

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Hiroshi Koike

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Magdalena Markowicz-Piasecka

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.

Sources (141 au total)

Outcomes after transanal proctectomy with ileal pouch-anal anastomosis in adolescents.

The aim of this study was to describe our initial surgical and functional outcomes of transanal ileal pouch anastomosis (Ta-IPAA) in adolescents.... A total of 16 adolescents' age ≤ 19 underwent consecutive Ta-IPAA on the indication ulcerative colitis (UC) or familiar adenomatous polyposis (FAP), between January 2018 and September 2022. Primary ou... Thirteen adolescents with UC and three with FAP underwent Ta-IPAA. The median age of UC patients was 16. They had a colectomy on the indication UC followed by a Ta-IPAA. Median operating time was 247 ... Ta-IPAA approach in children seems to be feasible, safe and offers acceptable functional results....

Impact of Total Neoadjuvant Therapy on Postoperative Outcomes After Proctectomy for Rectal Cancer.

Total neoadjuvant therapy is an alternative to neoadjuvant chemoradiation alone for rectal cancer and has the benefits of more completion of planned therapy, increased downstaging, earlier treatment o... The study aimed to determine the impact of total neoadjuvant therapy on postoperative complications compared with neoadjuvant chemoradiation alone.... Retrospective cohort study.... Single tertiary referral center.... The patient included was a stage II/III rectal cancer patient who underwent total neoadjuvant therapy or long-course neoadjuvant chemoradiation followed by surgical resection from 2018-2020.... The main outcome measures included severe postoperative complications (Clavien-Dindo grade ≥3).... Of 181 patients, 86 (47.5%) underwent total neoadjuvant therapy and 95 (52.5%) underwent neoadjuvant chemoradiation. There was no difference in severe postoperative complications or any complications.... Selection bias uncontrolled by modeling.... We found no difference in risk of postoperative complications between patients who received total neoadjuvant therapy vs neoadjuvant chemoradiation. Total neoadjuvant therapy patients had longer opera... ANTECEDENTES:La terapia neoadyuvante total es una alternativa a la quimiorradiación neoadyuvante sola para el cáncer de recto y tiene los beneficios de una mayor finalización de la terapia planificada...

Risk factors for ischemia/necrosis of the colonic stump after proctectomy and delayed coloanal anastomosis.

Delayed coloanal anastomosis (DCAA) is a two-stage procedure. DCAA has been increasingly reused in recent years in the management of rectal cancer. Such increased use of DCAA has highlighted the compl... All patients who underwent a proctectomy with a DCAA were included in this retrospective single-centre study from November 2012 to June 2022. Two groups of patients were defined: patients with a well ... During the study period, 43 patients underwent DCAA. Amongst them, 32 (75%) had a well-vascularized colonic stump (well-vascularized group) and 11 (25%) ischemia of the colonic stump (ischemic group).... This study highlights clear risk factors for ischemia/necrosis of the colonic stump after proctectomy with DCAA....

Benefits of a laparoscopic approach for second colorectal resection after colectomy or proctectomy -a retrospective study.

A laparoscopic approach generally provides several benefits in patients who undergo colon or rectal surgery without jeopardizing oncological outcomes. However, there is a paucity of studies on compara... From patients with colorectal disease who underwent surgery between 2008 and 2022 at our hospital, we collected 69 consecutive patients who had previous colorectal surgery for this retrospective study... Four patients (11%) of the Lap group needed conversion to laparotomy. The intraoperative blood loss was lower in the Lap group than the Op group (median: 45 ml vs. 205 ml, p = 0.001). The time to firs... Laparoscopic surgery appeared feasible and beneficial for selected patients undergoing second colorectal resection after colectomy or proctectomy regarding blood loss and bowel function recovery witho...

Robotic versus laparoscopic proctectomy: a comparative study of short-term economic and clinical outcomes.

Although several studies compare the clinical outcomes and costs of laparoscopic and robotic proctectomy, most of them reflect the outcomes of the utilisation of older generation robotic platforms. Th... Consecutive patients undergoing laparoscopic and robotic proctectomy between January 2017 and June 2020 in a public quaternary centre were included. Demographic characteristics, baseline clinical, tum... During the study period, 113 patients underwent minimally invasive proctectomy. Of these, 81 (71.7%) underwent a robotic proctectomy. A robotic approach was associated with a lower conversion rate (2.... Robotic proctectomy was associated with increased theatre costs but not with increased overall inpatient costs within a public healthcare setting. Conversion was less common for robotic proctectomy at...

Artificial Intelligence Hybrid Survival Assessment System for Robot-Assisted Proctectomy: A Retrospective Cohort Study.

Robotic-assisted proctectomy (RAP) has emerged as the predominant surgical approach for patients with rectal cancer in recent years; although good postoperative patient recovery with accurate predicti... This study used the electronic health records of 506 RAP participants, including a National Specialist Center for da Vinci Robotic Colorectal Surgery (NSCVRCS) meta cohort, and an independent external... The consistent evaluation of discrimination, calibration, generalization, and prognostic value across cohorts reaffirmed the accuracy and robust extrapolation capability of this system. The 10 feature... This study introduces a promising and informative tool, the RAP-AIscore, which can be explained through nomograms for interpreting clinical outcomes. It facilitates postoperative risk stratification m...

Predictors and survival outcomes of having less than 12 harvested lymph nodes in proctectomy for rectal cancer.

Current recommendations suggest that a minimum of 12 lymph nodes (LNs) should be harvested during curative rectal cancer resection. We aimed to assess predictors and survival outcomes of harvesting < ... A retrospective case-control analysis of factors associated with harvesting < 12 LNs in rectal cancer surgery was conducted. Data were derived from the National Cancer Database 2010-2019. Univariate a... 67,529 patients (60.8% male; mean age: 61.2 ± 12.5 years) were included. Median number of harvested LNs was 15 (IQR: 11-20); 27.1% of patients had < 12 harvested LNs. Independent predictors of harvest... Older age, open resection, and neoadjuvant therapy were independent predictors of < 12 harvested LNs. Conversely, higher clinical TNM stage and tumor grade, coloanal anastomosis, and minimally invasiv...

Ratio of Economy of Motion: A New Objective Performance Indicator to Assign Consoles During Dual-Console Robotic Proctectomy.

Our group investigates objective performance indicators (OPIs) to analyze robotic colorectal surgery. Analyses of OPI data are difficult in dual-console procedures (DCPs) as there is currently no reli... A colorectal surgeon and fellow reviewed 21 unedited, dual-console proctectomy videos with no information to identify the operating surgeons. The reviewers watched a small number of random tasks and a... A total of 1811 individual surgical tasks were recorded during 21 proctectomy videos. A median of 6.5 random tasks (137 total) were reviewed during each video, and the remainder of task assignments we... We developed and validated rEOM as an accurate, efficient, and scalable OPI to assign individual surgical tasks to appropriate surgeons during DCPs. This new resource will be useful to everyone involv...